ProQR Therapeutics BV
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -22.0% | -36.4% | -7.8% | +72.9% | +19.7% | -8.4% | +97.3% | -23.3% | -16.7% | +14.2% | -23.9% | |
| – | -22.9% | -38.4% | -7.2% | +78.5% | +18.8% | -23.9% | +122.4% | -24.3% | -18.9% | +19.2% | -26.2% | |
| – | -24.5% | -39.4% | -7.5% | +82.8% | +19.0% | -26.2% | +129.8% | -52.6% | +29.9% | +17.8% | -29.8% | |
| – | -24.5% | -39.4% | -7.5% | +82.8% | +19.0% | -26.2% | +129.8% | -52.6% | +29.9% | +17.8% | -29.8% | |
| – | +79.2% | +1.1% | -65.9% | +120.7% | +7.5% | -26.7% | -4.4% | +6,426.8% | -97.7% | +49.9% | +184.6% | |
| – | +67.3% | +113.9% | -93.8% | +1,131.5% | -62.2% | +11.5% | -29.7% | -97.4% | -100.0% | – | – | |
| – | +26.6% | +56.3% | -27.1% | -25.6% | +30.9% | +662.3% | -6.1% | -7.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -22.3% | -38.0% | -50.7% | -100.0% | – | – | – | – | – | – | – | |
| – | +58.4% | +16.8% | +26.4% | +6.1% | +51.6% | +94.0% | +112.3% | +1.9% | -4.6% | -22.9% | -9.5% | |
| – | +63.4% | +18.8% | +44.1% | -20.0% | +51.2% | +2.1% | +149.0% | -28.6% | +68.7% | +6.6% | -5.4% | |
| – | -60.4% | -100.0% | – | -99.7% | +13,546.4% | +206.8% | +144.7% | -42.1% | -57.0% | +159.4% | +12.9% | |
| – | -36.3% | -64.0% | +89.5% | -79.4% | +270.0% | -45.9% | -19.7% | +92.6% | +306.9% | -99.0% | +2,012.4% | |
| – | +16.5% | +18.1% | -7.2% | +77.6% | +35.4% | +27.4% | +142.9% | -89.1% | +0.5% | – | – | |
| – | -26.3% | -42.5% | -15.7% | +96.1% | +14.2% | -34.0% | +85.3% | -44.7% | -36.1% | +100.6% | -36.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +5.4% | +0.0% | +8.7% | +34.2% | +20.5% | +22.0% | +28.2% | +11.6% | +13.1% | +0.8% | +29.0% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.